TY - JOUR
T1 - Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients
T2 - an Italian retrospective multicenter study
AU - Arcari, Annalisa
AU - Chiappella, Annalisa
AU - Spina, Michele
AU - Zanlari, Luca
AU - Bernuzzi, Patrizia
AU - Valenti, Vanessa
AU - Tani, Monica
AU - Marasca, Roberto
AU - Cabras, Maria Giuseppina
AU - Zambello, Renato
AU - Santagostino, Alberto
AU - Ilariucci, Fiorella
AU - Carli, Giuseppe
AU - Musto, Pellegrino
AU - Savini, Paolo
AU - Marino, Dario
AU - Ghio, Francesco
AU - Gentile, Massimo
AU - Cox, Maria Christina
AU - Vallisa, Daniele
PY - 2016
Y1 - 2016
N2 - Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not suitable for high dose chemotherapy with autologous stem cell transplantation (ASCT) has a dismal prognosis and no standard therapy. We designed an Italian multicenter retrospective study aimed at evaluating the safety and efficacy of rituximab plus bendamustine (R–B) as salvage treatment in patients not eligible for ASCT because of age and/or comorbidity or in patients with post-ASCT recurrence. Fifty-five patients with a median age of 76 years were included. The overall response rate was 50%, including 28% complete remission and 22% partial remission. The median overall survival (OS) was 10.8 months. The median progression free survival (PFS) was 8.8 months. Eleven patients are still alive and in complete remission at last follow-up (12–71 months). Toxicity was moderate, mainly grades 1 and 2. R–B showed promising efficacy results with an acceptable toxicity profile and should be further investigated, possibly in combination with novel drugs.
AB - Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not suitable for high dose chemotherapy with autologous stem cell transplantation (ASCT) has a dismal prognosis and no standard therapy. We designed an Italian multicenter retrospective study aimed at evaluating the safety and efficacy of rituximab plus bendamustine (R–B) as salvage treatment in patients not eligible for ASCT because of age and/or comorbidity or in patients with post-ASCT recurrence. Fifty-five patients with a median age of 76 years were included. The overall response rate was 50%, including 28% complete remission and 22% partial remission. The median overall survival (OS) was 10.8 months. The median progression free survival (PFS) was 8.8 months. Eleven patients are still alive and in complete remission at last follow-up (12–71 months). Toxicity was moderate, mainly grades 1 and 2. R–B showed promising efficacy results with an acceptable toxicity profile and should be further investigated, possibly in combination with novel drugs.
KW - Bendamustine
KW - diffuse large B-cell lymphoma
KW - elderly
KW - rituximab
UR - http://www.scopus.com/inward/record.url?scp=84949782021&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84949782021&partnerID=8YFLogxK
U2 - 10.3109/10428194.2015.1106536
DO - 10.3109/10428194.2015.1106536
M3 - Article
SP - 1823
EP - 1830
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
ER -